Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLD-1 in Advanced Solid Tumors
NCT03387917Phase 1Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2018
- Primary completion
- Sep 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TLD-1 in solid tumor, breast cancer, ovarian cancer and 2 more (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoints: Dose-limiting toxicity at 3 weeks, Volume of distribution at 2 months and 5 more. Started Nov 2018; status: terminated.
02
Drugs
TLD-1
03
Conditions
solid tumorbreast cancerovarian canceruterine cancersarcoma
Beyond the preview
Go deeper on NCT03387917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387917.